Acyclic Carbon To Carbon Unsaturation Patents (Class 514/713)
-
Patent number: 11911354Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.Type: GrantFiled: December 15, 2021Date of Patent: February 27, 2024Assignee: BASFInventors: Hilde Steineger, David Alan Fraser, Tore Skjæret
-
Patent number: 11666631Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: GrantFiled: July 8, 2019Date of Patent: June 6, 2023Assignee: Arch Biopartners, Inc.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
-
Patent number: 10722481Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.Type: GrantFiled: October 31, 2018Date of Patent: July 28, 2020Assignee: BASF ASInventor: Hilde Steineger
-
Patent number: 8889731Abstract: This invention relates to compositions of one or more compounds that incorporate one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties, or one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties and one or more hydroxyl groups, used in effective amount in formulations, including emulsions, to repel blood-feeding ectoparasitic arthropods, including mosquitoes, and to deter them from landing and feeding when applied to the skin, clothing or environment of animals, including humans. Said compounds can include, but are not limited to, 8-allyl-sulfanyloctan-1-ol. This invention also relates to compositions comprising one or more of said compounds in further combination with other arthropod repellent and deterrent compounds, including vanillin. These compounds may be formulated with inert ingredients to form a liquid, gel, paste, soap, spray, aerosol or powder.Type: GrantFiled: March 28, 2008Date of Patent: November 18, 2014Assignee: Contech Enterprises Inc.Inventors: Regine M. Gries, Gerhard G. Gries, Grigori Khaskin, Norman Avelino, Cory Campbell
-
Patent number: 8808702Abstract: Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.Type: GrantFiled: December 12, 2007Date of Patent: August 19, 2014Assignee: Temple University-of the Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Patent number: 8784871Abstract: The present invention relates to a method for reducing the production of methane emanating from the digestive activities of a ruminant and or for improving ruminant animal performance by using, as active compound at least one nitrooxy alkanoic acid and/or derivative thereof, which is administrated to the animal together with the feed. The invention also relates to the use of these compounds in feed and feed additives such as premix, concentrates and total mixed ration (TMR) or in the form of a bolus.Type: GrantFiled: December 10, 2010Date of Patent: July 22, 2014Assignee: DSM IP Assets B.V.Inventors: Stephane Duval, Maik Kindermann
-
Patent number: 8741966Abstract: The present disclosure relates to lipid compounds of formula (I): wherein: R1 is chosen from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and are chosen from hydrogen and a C1-C6 alkyl; X is chosen from O, S, SO, SO2, Si, and Se; n=1 or 3; and P1 is chosen from hydrogen; a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P2, P3, and P4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P5 is chosen from hydrogen and a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof.Type: GrantFiled: November 6, 2008Date of Patent: June 3, 2014Assignee: Pronova Biopharma Norge ASInventor: Anne Kristin Holmeide
-
Patent number: 8673888Abstract: The present invention provides a therapeutic agent of kidney cancer, which comprises FK228 of the formula (I) or a salt thereof. FK228 or a salt thereof, which is an active ingredient in the present invention, shows a superior antitumor activity in vivo against kidney cancer.Type: GrantFiled: March 27, 2003Date of Patent: March 18, 2014Assignees: The United States of America, represented by the Secretary, Department of Health and Human Services, Astellas Pharma Inc.Inventors: Yoshinori Naoe, Susan E. Bates
-
Patent number: 8501206Abstract: A liquid concentrate for preserving cosmetic products which includes a combination of carboxylic component being sodium benzoate and an alcohol component being a mixture of phenoxy ethanol and benzyl alcohol, in a water, where the combination is greater than 45% by weight of the liquid concentrate.Type: GrantFiled: May 17, 2012Date of Patent: August 6, 2013Assignee: Air Liquide Sante (International)Inventors: Wolfgang Beilfuss, Gisela Hahn, Klaus Weber, Ralf Gradke
-
Patent number: 8492442Abstract: It is intended to provide a safe composition for treating a disease or condition relating to autonomic nervous activity which has an autonomic nervous control effect; in particular, an effect of enhancing parasympathetic nervous activity. Thus, a medicinal composition, a food or a drink containing L-phenyl lactic acid and/or D-phenyl lactic acid and having an autonomic nervous control effect is provided.Type: GrantFiled: March 28, 2008Date of Patent: July 23, 2013Assignee: Suntory Holdings LimitedInventors: Yoshinori Beppu, Nobuo Tsuruoka, Hajime Komura, Katsuya Nagai
-
Publication number: 20130123326Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.Type: ApplicationFiled: January 4, 2013Publication date: May 16, 2013Applicants: REGION MIDTJYLLAND, AARHUS UNIVERSITETInventors: AARHUS UNIVERSITET, REGION MIDTJYLLAND
-
Patent number: 8278349Abstract: Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.Type: GrantFiled: November 6, 2006Date of Patent: October 2, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Liat Goldberg, Michael Brownstein
-
Patent number: 8222295Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.Type: GrantFiled: August 5, 2009Date of Patent: July 17, 2012Assignee: Centre de Recherche sur les Biotechnologies MarinesInventor: Samuel Fortin
-
Patent number: 8197833Abstract: The invention relates to a liquid concentrate for preserving cosmetic products which comprises a combination of carboxylic acid salts chosen from the salts of benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydracetic acid, formic acid or 10-undecylenic acid and alcohols chosen from 2-phenoxyethanol, benzyl alcohol, phenethyl alcohol, 1-phenoxypropan-2-ol, 3-(4-chlorophenoxy)-1,2-propanediol, chlorobutanol or 2,4-dichlorobenzyl alcohol in a solvent, where the active ingredient content is greater than 45% by weight.Type: GrantFiled: January 13, 2009Date of Patent: June 12, 2012Assignee: Air Liquide Sante (International)Inventors: Wolfgang Beilfuss, Gisela Hahn, Klaus Weber, Ralf Gradke
-
Publication number: 20120095048Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.Type: ApplicationFiled: February 19, 2010Publication date: April 19, 2012Applicants: REGION MIDT JYLLAND, AARHUS UNIVERSITETInventors: Henrik Amtoft Neubauer, Ove Kjaer Wiborg, Henrik Helligsø Jensen
-
Publication number: 20120058965Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.Type: ApplicationFiled: June 17, 2011Publication date: March 8, 2012Inventors: William A. GODDARD, III, Mark MENNA, Stephen PANDOL, Ravinder ABROL
-
Patent number: 8088756Abstract: Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists.Type: GrantFiled: August 18, 2005Date of Patent: January 3, 2012Assignee: Concordia Pharmaceuticals, Inc.Inventor: Victor J. Bauer
-
Publication number: 20110092578Abstract: The present invention provides compounds and methods of using of the compounds as anti-infective and anthelminitc agents. In a preferred embodiment, the present invention provides the following compound of Formula III: wherein: R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is OH or CH(2n+1)O, wherein n is 1-10; R2 is OH or CH(2n+1)O, where n is 1-10; W is alkyl, phenyl, halophenyl, pyridyl, piperidyl, or a substituted or unsubstituted aryl group, including unsubstituted and substituted aromatic heterocycles; and L is an optional linker or linking group selected from O, S, NH, CF2, or CH2, and x=0 or 1, i.e., if x=0, no linking group is present.Type: ApplicationFiled: December 20, 2010Publication date: April 21, 2011Inventors: Aaron P. Monte, M. Shahjahan Kabir, Marc A. Rott, William R. Schwan, James M. Cook, III, Jennifer A. Miskowski
-
Patent number: 7855226Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.Type: GrantFiled: March 17, 2005Date of Patent: December 21, 2010Assignee: Allergan, Inc.Inventors: Yariv Donde, Jeremiah H. Nguyen, Karen M. Kedzie, Daniel W. Gil, John E. Donello, Wha-Bin Im
-
Publication number: 20100280109Abstract: The present disclosure relates to lipid compounds of formula (I): wherein: R1 is chosen from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and are chosen from hydrogen and a C1-C6 alkyl; X is chosen from O, S, SO, SO2, Si, and Se; n=1 or 3; and P1 is chosen from hydrogen; a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P2, P3, and P4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P5 is chosen from hydrogen and a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof.Type: ApplicationFiled: November 6, 2008Publication date: November 4, 2010Inventor: Anne Kristin Holmeide
-
Patent number: 7700657Abstract: Novel vitamin D analogs, markedly active in the fields of cell proliferation and differentiation, are selected from among (4E,6E)-7-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl}-3-ethylnona-4,6-dien-3-ol, (E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, (3E,5E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)-phenyl]-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, (E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)ethyl]phenyl}-1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, and (3E,5E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, and the geometric isomers thereof and these compounds in which one or more of the hydroxyl functions are protected by a protective group —(C?O)—R, in which R is a linear or branched alkyl radical having from 1 to 6 carbon atoms, an aryl radical having from 6 to 10 carbon atoms, or an aralkyl radical having from 7 to 11 carbon atoms, the aryl radical or the aralkyl radical optionalType: GrantFiled: November 24, 2003Date of Patent: April 20, 2010Assignee: Galderma Research & DevelopmentInventor: Jean-Michel Bernardon
-
Publication number: 20100028368Abstract: Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.Type: ApplicationFiled: December 12, 2007Publication date: February 4, 2010Applicant: TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: E. Premkumar Reddy, M.V. Ramana Reddy
-
Publication number: 20090192212Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.Type: ApplicationFiled: February 23, 2009Publication date: July 30, 2009Applicant: Encore Health, LLCInventors: William Garner, Margaret Garner, Ronald D. Blum
-
Publication number: 20090069407Abstract: This invention relates to compositions of one or more compounds that incorporate one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties, or one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties and one or more hydroxyl groups, used in effective amount in formulations, including emulsions, to repel blood-feeding ectoparasitic arthropods, including mosquitoes, and to deter them from landing and feeding when applied to the skin, clothing or environment of animals, including humans. Said compounds can include, but are not limited to, 8-allyl-sulfanyloctan-1-ol. This invention also relates to compositions comprising one or more of said compounds in further combination with other arthropod repellent and deterrent compounds, including vanillin. These compounds may be formulated with inert ingredients to form a liquid, gel, paste, soap, spray, aerosol or powder.Type: ApplicationFiled: March 28, 2008Publication date: March 12, 2009Applicant: PHERO TECH INTERNATIONAL INC.Inventors: Regine M. GRIES, Gerhard G. GRIES, Grigori KHASKIN, Norman AVELINO, Cory CAMPBELL
-
Patent number: 6787573Abstract: The invention relates to the field of antiviral agents, and more specifically to antiviral therapy. The invention provides use of at least one compound or mixture of compounds of the general formula or a functional equivalent or pharmaceutically acceptable salt or hydrate thereof for the production of a pharmaceutical composition for the treatment of a viral infection.Type: GrantFiled: March 14, 2002Date of Patent: September 7, 2004Assignees: Universiteit Utrecht, Universitair Medisch Centrum UtrechtInventor: Johannes Servatius Leonardus Maria Nottet
-
Publication number: 20040171698Abstract: Antimicrobially active 4-methyl-4-aryl-2-pentanols of the Formula 1 below, methods for the preparation of these compounds and their use as antimicrobial active compounds are described.Type: ApplicationFiled: March 3, 2004Publication date: September 2, 2004Inventors: Gerhard Schmaus, Holger Joppe
-
Patent number: 6743419Abstract: A method of reducing the rate of mammalian hair growth includes topically applying a composition containing a sulfhydryl reactive compound to the skin.Type: GrantFiled: June 5, 1997Date of Patent: June 1, 2004Assignee: The Gillette CompanyInventors: Douglas Shander, Gurpreet S. Ahluwalia, Diana Marks-Del Grosso
-
Patent number: 6689922Abstract: The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.Type: GrantFiled: July 26, 2001Date of Patent: February 10, 2004Assignee: Galderma Research & Development S.N.C.Inventor: Jean-Michel Bernardon
-
Publication number: 20030171441Abstract: The invention relates to the field of antiviral agents, and more specifically to antiviral therapy.Type: ApplicationFiled: March 14, 2002Publication date: September 11, 2003Inventor: Johannes Servatius Leonardus Maria Nottet
-
Patent number: 6608061Abstract: A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar1—S—R1—S—Ar2 wherein R1 represents a nonmetal bridging group; Ar1 and Ar2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.Type: GrantFiled: February 14, 2000Date of Patent: August 19, 2003Assignees: Kyoma Hakko Kogyo Co., Ltd., Fuji Photo Film Co., Ltd.Inventors: Yoshiyuki Yonetani, Takeshi Takahashi, Yuko Kanda, Tamio Mizukami, Tatsuya Tamaoki, Shun-ichi Ikeda, Masanobu Takashima, Naoki Asanuma, Tadashi Inaba, Hiroshi Takeuchi, Hiroshi Kawamoto, Yoshihisa Tsukada, Masato Satomura, Hiroshi Kitaguchi
-
Patent number: 6605641Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z), 14(Z)-dienoic acid and 20-, 21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z), 15(Z)-dienoic acid.Type: GrantFiled: December 14, 2001Date of Patent: August 12, 2003Assignee: MCW Research FoundationInventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
-
Patent number: 6596769Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.Type: GrantFiled: December 14, 2001Date of Patent: July 22, 2003Assignee: MCW Research FoundationInventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
-
Publication number: 20030018070Abstract: A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof:Type: ApplicationFiled: February 14, 2000Publication date: January 23, 2003Inventors: YOSHIYUKI YONETANI, TAKESHI TAKAHASHI, YUKO KANDA, TAMIO MIZUKAMI, TATSUYA TAMAOKI, SHUN-ICHI IKEDA, MASANOBU TAKASHIMA, NAOKI ASANUMA, TADASHI INABA, HIROSHI TAKEUCHI, HIROSHI KAWAMOTO, YOSHIHISA TSUKADA, MASATO SATOMURA, HIROSHI KITAGUCHI
-
Publication number: 20020143069Abstract: The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF&agr;)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA4 and ATL analogs each inhibited TNF&agr;-stimulated superoxide anion generation and IL-1&bgr; release by human PMN.Type: ApplicationFiled: January 11, 2002Publication date: October 3, 2002Inventor: Charles N. Serhan
-
Patent number: 6444709Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.Type: GrantFiled: February 7, 2000Date of Patent: September 3, 2002Assignee: Galderma Research & Development S.N.C.Inventors: Philippe Diaz, Jean-Michel Bernardon
-
Patent number: 6395781Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.Type: GrantFiled: February 23, 1999Date of Patent: May 28, 2002Assignee: MCW Research FoundationInventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
-
Patent number: 6387959Abstract: The invention relates to the field of antiviral agents, and more specifically to antiviral therapy. The invention provides use of at least one compound or mixture of compounds of the general formula or a functional equivalent or pharmaceutically acceptable salt, ester or hydrate thereof for the treatment of a viral infection.Type: GrantFiled: June 30, 2000Date of Patent: May 14, 2002Assignees: Universiteit Utrecht, Universitair Medisch Centrum UtrechtInventor: Johannes Servatius Leonardus Maria Nottet
-
Patent number: 6239111Abstract: The present invention discloses the use, in the manufacture of a preventive and therapeutic drug of a brain disease, of a compound represented by formula (1): CH2═CH—CH2—S(O)n—R (1) [wherein R represents a hydrogen atom, an alkyl group, an alkenyl group, a substituted alkyl group, a substituted alkenyl group, an alkylthio group, an alkenylthio group, a phenyl group, a substituted phenyl group, a heterocyclic group, or a group derived from an amino acid or an oligopeptide by deletion of one hydrogen atom, and which group may have a protective group; and n is 0, 1, or 2], a glycoside thereof, or a salt of the compound or the glycoside. The drug of the present invention for ameliorating brain diseases, inhibiting reduction of brain neurons and promoting branching of neurites, is useful for the prevention and treatment of brain diseases such as dementia in association with degeneration and sloughing of brain neurons.Type: GrantFiled: January 26, 1998Date of Patent: May 29, 2001Assignee: Wakunaga Pharmaceutical Co., Ltd.Inventors: Toru Moriguchi, Hiromichi Matsuura, Hiroshi Saito
-
Patent number: 6114572Abstract: The present invention provides compounds of the formula ##STR1## wherein X is selected from the group consisting of ##STR2## Y is thio, oxy or a methylene group; Z is hydrogen or --C(O)--(CH.sub.2).sub.m --Q wherein Q is hydrogen or --COOH and m is an integer 1, 2, 3 or 4;R.sub.1 is C.sub.1 -C.sub.6 alkyl; andR.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl;or a stereoisomer thereof; useful for the treatment of atherosclerosis and chronic inflammatory disorders; for inhibiting cytokine-induced expression of VCAM-1 and/or ICAM-1; for inhibiting the peroxidation of LDL lipid; for lowering plasma cholesterol; and as anti-oxidant chemical additives useful for preventing oxidative deterioration in organic materials.Type: GrantFiled: November 19, 1997Date of Patent: September 5, 2000Assignee: Hoechst Marion Roussel, Inc.Inventors: Roger A. Parker, Paul S. Wright, Steven J. Busch, Kim S. Chen, Mark T. Yates
-
Patent number: 6106821Abstract: The invention relates to fly attractant compositions that comprise at least one volatile short chain carboxylic acid, at least one organic sulfide and at least one nitrogen heterocycle. In a preferred embodiment the composition additionally comprises at least one ammonia-releasing compound. In a particularly preferred example, the composition is preparable by combining, for example, the carboxylic acid, the organic sulfide and the nitrogen heterocycle. The invention also relates to an insect trap comprising a means for retaining flies and an insect attractant composition of this invention. The trap is useful in commercial, residential and livestock facilities.Type: GrantFiled: December 5, 1997Date of Patent: August 22, 2000Assignee: Iowa State University Research Foundation, Inc.Inventors: Thomas C. Baker, Allard A. Cosse
-
Patent number: 6103753Abstract: An intimal thickening inhibitory agent comprising, as an active ingredient, a compound represented by formula (1): ##STR1## wherein X represents an oxygen atom or a group of formula (2): ##STR2## wherein n represents an integer of from 0 to 2, R.sub.1 represents a hydrogen atom or an acyl group; R.sub.2 represents a hydrogen atom, a lower alkyl group or a lower alkenyl group; R.sub.3 represents a lower alkyl group; and R.sub.4, R.sub.5, and R.sub.6, which may be the same or different, each represent a hydrogen atom or a substituted or unsubstituted alkyl group; or R.sub.3 and R.sub.4 may be taken together to form a 5-membered ring; or R.sub.5 and R.sub.6 may be taken together to form a cycloalkyl group; provided that R.sub.6 is nil when R.sub.3 and R.sub.4 are taken together to form benzofuran or benzo[b]thiophene.Type: GrantFiled: May 6, 1998Date of Patent: August 15, 2000Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Osamu Cynshi, Reiko Sekimori, Yoshiaki Kato
-
Patent number: 5981603Abstract: This invention relates to compounds, compositions, uses and methods for inhibiting viral and retroviral replication and for treating viral and retroviral infections via the administration of various compounds, including antioxidants, preferably compounds corresponding to the formula ##STR1## wherein n=1, 2, 3, or 4; m=0 or 1; X is O, S or CH.sub.2 ; R.sub.1 is hydrogen or tertiary butyl or lower alkyl of from one to six carbon atoms, inclusive; R.sub.2 is tertiary butyl or lower alkyl of from one to six carbon atoms, inclusive; and R.sub.3 is hydrogen or alkyl or aryl or mixed alkyl/aryl, containing a total of 5-25 carbon atoms.Type: GrantFiled: February 28, 1997Date of Patent: November 9, 1999Assignee: Vyrex CorporationInventor: Sheldon S. Hendler
-
Patent number: 5972993Abstract: A method for treating skin conditions, such as rosacea and sensitive skin, that manifest as a tendency towards flushing and blushing is provided. Also provided herein, are compositions for the treatment of rosacea and sensitive skin that are comprised of at least one antioxidant selected from the following groups of antioxidants: (a) phenolic compounds that contain at least one hydroxyl group connected directly to a benzene ring and to another unsaturated chemical grouping, (b) sulfur-containing compounds that contain at least one sulfhydryl groups or sulfur-containing compounds that contain at least one disulfide group, or (c) polyene compounds that have conjugated systems of double bonds.Type: GrantFiled: March 20, 1998Date of Patent: October 26, 1999Assignee: Avon Products, Inc.Inventor: Dmitri Ptchelintsev
-
Patent number: 5869506Abstract: The present invention provides a fluoropropene compound represented by Formula I: ##STR1## wherein R.sup.1 represents a C.sub.1 -C.sub.10 alkyl group or other groups, Z represents an oxygen atom or other groups, R.sup.2, R.sup.3, and R.sup.4 each independently represent a C.sub.1 -C.sub.3 alkyl group or other groups, r represents an integer of 0 to 2, and X represents a halogen atom or other groups.Type: GrantFiled: January 30, 1997Date of Patent: February 9, 1999Assignee: Sumitomo Chemical Company, LimitedInventors: Keiichi Izumi, Hiroshi Ikegami, Masaya Suzuki, Noriyasu Sakamoto, Hirotaka Takano
-
Patent number: 5840724Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.Type: GrantFiled: June 24, 1997Date of Patent: November 24, 1998Assignee: Rhone-Poulenc Rorer LimitedInventors: Garry Fenton, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Keith Alfred James Stuttle, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher
-
Patent number: 5807899Abstract: This invention describes the new triphenylethylenes of general formula I ##STR1## in which n means an integer from 1 to 10,R' means a sulfur-containing organic radical,R" means a hydrogen atom, an iodine atom or a hydroxy groups,E means a hydrogen atom,G means a hydrogen atom orE and G together mean a methylene bridge.The new compounds have strong antiestrogenic properties and are suitable for the production of pharmaceutical agents, for example for treating breast cancer.Type: GrantFiled: July 5, 1996Date of Patent: September 15, 1998Assignee: Schering AktiengesellschaftInventors: Rolf Bohlmann, Joseph Heindl, Hermann Kunzer, Yukishige Nishino, Karsten Parczyk, Martin Schneider
-
Patent number: 5679696Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.Type: GrantFiled: June 7, 1995Date of Patent: October 21, 1997Assignee: Rhone-Poulenc Rorer LimitedInventors: Garry Fenton, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Keith Alfred James Stuttle, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher
-
Patent number: 5430062Abstract: The present invention relates to stilbene derivatives which possess utility as anti-cancer agents. The compounds can be used to treat cancers which are susceptible to treatment therewith, and can be utilized in a method of treating such cancers. Pharmaceutical compositions containing the compounds are disclosed. Three preferred compounds among those disclosed are (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene, (Z)-1-(4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene, and 4-methyl-3',4',5'-trimethoxybenzylaniline hydrochloride.Type: GrantFiled: June 23, 1993Date of Patent: July 4, 1995Assignee: Research Corporation Technologies, Inc.Inventors: Mark S. Cushman, Ernest Hamel
-
Patent number: 5393776Abstract: This invention relates to structurally novel acyclic tocotrienol analogs, which are useful for cholesterol/lipid lowering in cases of hypercholesterolemia and hyperlipidemia, and for atherosclerosis. Also provided are pharmaceutical compositions and a method of use employing those compositions.Type: GrantFiled: May 13, 1994Date of Patent: February 28, 1995Assignee: Bristol-Myers Squibb CompanyInventor: Bradley C. Pearce
-
Patent number: RE37087Abstract: There are provided new alkane and alkoxyalkane derivatives of the general formula I in which R1, R2, R3, R4 and A have the meanings given in the description, processes for their preparation and insecticidal and acaricidal compositions containing these compounds.Type: GrantFiled: June 20, 1991Date of Patent: March 6, 2001Assignee: Schering AktiengesellschaftInventors: Helga Franke, Heinrich Franke, Hans-Rudolf Kruger, Hartmut Joppien, Dietrich Baumert, David Giles